Last reviewed · How we verify
Ranibizumab + deferred laser
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor.
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor. Used for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following retinal vein occlusion.
At a glance
| Generic name | Ranibizumab + deferred laser |
|---|---|
| Also known as | Lucentis, anti-VEGF drug |
| Sponsor | Jaeb Center for Health Research |
| Drug class | anti-VEGF agent |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
VEGF-A is a protein that promotes angiogenesis, the formation of new blood vessels. By inhibiting VEGF-A, ranibizumab reduces the growth of new blood vessels in the retina, which can help slow vision loss in conditions such as age-related macular degeneration.
Approved indications
- Treatment of neovascular (wet) age-related macular degeneration
- Treatment of macular edema following retinal vein occlusion
Common side effects
- Intraocular inflammation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (PHASE3)
- Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser (PHASE4)
- Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranibizumab + deferred laser CI brief — competitive landscape report
- Ranibizumab + deferred laser updates RSS · CI watch RSS
- Jaeb Center for Health Research portfolio CI